Tests an early lipid-lowering care program after heart-related hospital stays
Tests an early cholesterol-lowering support program in adults with heart disease in Asia-Pacific.
Key facts
- Who runs it
- Stephen Nicholls
- Where
- Pyeongchon and Seoul, South KoreaSee the 2 sitesAlso in 8 other countries, 20 sites
- Trial code
- Registry title
- Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 15 Sept 2022
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Early Intervention
- Record updated
- 8 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who were admitted to hospital with a Type I heart attack (myocardial infarction). It tests a multi-part programme to lower cholesterol.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Admission to hospital for a Type I myocardial infarction (heart attack).
- Biomarker or test result
- LDL cholesterol must not be below 1.4mmol/L (54 mg/dL) at the start.
Main reasons for not taking part
- LDL below 1.4mmol/L (54 mg/dL) at baseline
- Cannot give contact details of their primary care doctor or general practitioner
- Cannot give written informed consent
- Unlikely to survive more than 12 months
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- 18 years of age
- Admission for Type I myocardial infarction
Who cannot take part
- LDL <1.4mmol/L at baseline
- Unable to provide contact details of primary care physician/general practitioner
- Unable to provide written informed consent
- Unlikely to survive >12 months
Where in South Korea
Also in 8 other countries, 20 sites
- PyeongChon Hallym University Sacred Heart HospitalPyeongchon, South KoreaContact: Sang-Ho JoNot yet recruiting
- Kangnam Hallym University Sacred Heart HospitalSeoul, South KoreaContact: Jung-Rae ChoNot yet recruiting
About the trial
What the trial wants to find out
Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study.
Read full original descriptionShow less
Patients will be recruited during hospitalisation and be randomised to a multifaceted intervention to be delivered either 'early' (baseline) or 'late' (6 months), in a 1:1 fashion.
The 2 groups in the trial
- Early interventionExisting treatment, for comparison
Participants randomised to 'early' will receive the intervention at baseline through 6 months. while those randomised to 'late' will receive standard-of-care and represent a control arm over this period.
- Late interventionOther group
Those randomised to 'late' will receive standard-of-care and represent a control arm to the early intervention group.
Treatment: Early Intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Guideline Oriented Approach To Lipid Lowering In Asia-Pacific (GOAL-ASIA)
- Plain-language title
- Tests an early lipid-lowering care program after heart-related hospital staysGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 October 2026